Merck (NYSE:MRK) is preparing to launch a subcutaneously delivered formulation of their blockbuster cancer medication Keytruda for patient convenience as the company approaches a steep patent cliff ...

Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year. Despite strong performances from other pharmaceutical giants like Eli Lilly ...

Helen Branswell covered issues broadly related to infectious diseases, including outbreaks, preparedness, research, and vaccine development. A third monoclonal antibody product to protect babies ...

Merck (MRK) stock plummeted Tuesday after the Dow Jones stock topped Wall Street's fourth-quarter expectations, but delivered lighter-than-expected guidance for 2025. The company also withdrew its ...

Matthew Herper covers medical innovation — both its promise and its perils. Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Announcing better-than-expected financials for Q1 2025 on Thursday, Merck (NYSE:MRK) lowered its full-year outlook for earnings to account for various headwinds, including a $200M impact related to ...

Merck & Co., Inc. (NYSE:MRK) has surged over 38% in 2026 so far, outperforming the broader market. Merck is no longer being valued like a pharmaceutical company whose biggest challenge is looming ...

Merck lowered its full-year profit guidance, citing a charge tied to a recent licensing deal and $200 million in estimated additional costs for tariffs implemented to date. The company said the ...

Pfizer's 5.7% dividend yield towers over Merck's, yet that gap may signal something retirees cannot afford to ignore. Before you chase the bigger payout, the coverage numbers behind each dividend tell ...